DeDora Capital Inc. Sells 10,581 Shares of Abbott Laboratories (NYSE:ABT)

DeDora Capital Inc. lessened its position in shares of Abbott Laboratories (NYSE:ABT) by 43.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,053 shares of the healthcare product maker’s stock after selling 10,581 shares during the period. DeDora Capital Inc.’s holdings in Abbott Laboratories were worth $1,529,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. RPG Investment Advisory LLC boosted its holdings in shares of Abbott Laboratories by 113.4% during the second quarter. RPG Investment Advisory LLC now owns 382 shares of the healthcare product maker’s stock worth $35,000 after acquiring an additional 203 shares during the period. Crewe Advisors LLC boosted its holdings in shares of Abbott Laboratories by 278.4% during the third quarter. Crewe Advisors LLC now owns 367 shares of the healthcare product maker’s stock worth $40,000 after acquiring an additional 270 shares during the period. Bay Harbor Wealth Management LLC boosted its holdings in shares of Abbott Laboratories by 159.9% during the second quarter. Bay Harbor Wealth Management LLC now owns 447 shares of the healthcare product maker’s stock worth $41,000 after acquiring an additional 275 shares during the period. Islay Capital Management LLC bought a new stake in shares of Abbott Laboratories during the second quarter worth approximately $46,000. Finally, Arlington Partners LLC boosted its holdings in shares of Abbott Laboratories by 1,187.8% during the second quarter. Arlington Partners LLC now owns 528 shares of the healthcare product maker’s stock worth $48,000 after acquiring an additional 487 shares during the period. Institutional investors own 73.09% of the company’s stock.

A number of equities research analysts have recently issued reports on the company. Citigroup boosted their price objective on Abbott Laboratories from $110.00 to $130.00 and gave the stock a “buy” rating in a report on Friday, August 28th. Wolfe Research started coverage on Abbott Laboratories in a research note on Friday, September 11th. They issued an “outperform” rating and a $124.00 price target for the company. Argus boosted their price target on Abbott Laboratories from $110.00 to $125.00 in a research note on Thursday, July 23rd. BTIG Research reiterated a “hold” rating on shares of Abbott Laboratories in a research note on Thursday, August 27th. Finally, Stifel Nicolaus boosted their price target on Abbott Laboratories from $108.00 to $115.00 and gave the company a “buy” rating in a research note on Thursday, August 27th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and fourteen have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $115.18.

In related news, EVP Andrea F. Wainer sold 3,650 shares of the stock in a transaction on Wednesday, September 23rd. The stock was sold at an average price of $102.47, for a total value of $374,015.50. Following the completion of the sale, the executive vice president now directly owns 44,080 shares in the company, valued at $4,516,877.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Daniel Gesua Sive Salvadori sold 42,479 shares of the stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $111.86, for a total value of $4,751,700.94. Following the completion of the sale, the executive vice president now owns 144,912 shares of the company’s stock, valued at $16,209,856.32. The disclosure for this sale can be found here. Insiders have sold 84,919 shares of company stock valued at $9,283,128 over the last quarter. Company insiders own 1.70% of the company’s stock.

ABT traded down $0.38 during trading on Friday, hitting $109.10. 27,279 shares of the stock traded hands, compared to its average volume of 7,132,733. Abbott Laboratories has a twelve month low of $61.61 and a twelve month high of $114.19. The company has a market cap of $193.84 billion, a price-to-earnings ratio of 63.28, a PEG ratio of 2.98 and a beta of 0.92. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.57 and a quick ratio of 1.10. The business has a 50 day moving average price of $106.42 and a 200 day moving average price of $97.33.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, October 21st. The healthcare product maker reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.08. The company had revenue of $8.85 billion during the quarter, compared to the consensus estimate of $8.53 billion. Abbott Laboratories had a net margin of 9.89% and a return on equity of 17.34%. The company’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.84 earnings per share. On average, equities research analysts predict that Abbott Laboratories will post 3.3 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a dividend of $0.36 per share. The ex-dividend date of this dividend is Wednesday, October 14th. This represents a $1.44 annualized dividend and a dividend yield of 1.32%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 44.44%.

Abbott Laboratories Company Profile

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. Its Established Pharmaceutical Products segment offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.

Recommended Story: What are popular green investing opportunities?

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.